Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adenoviral Gene Therapy Death Will Be Explored By NIH rDNA Committee

Executive Summary

Safety and efficacy of adenoviral vectors for therapeutic application will be examined at the Dec. 9-10 meeting of the NIH Recombinant DNA Advisory Committee. The action follows the death of a teenager enrolled in a gene therapy trial at the University of Pennsylvania Medical Center.

You may also be interested in...



Gene Transfer Trials Should Require Sequencing Of Small Vectors - Cmte.

FDA should require complete sequencing of gene transfer vectors up to 40 kilo bases in size before initiation of a Phase I gene transfer therapy clinical trial, the Biological Response Modifiers Advisory Committee recommended Nov. 16.

Gene Transfer Trials Should Require Sequencing Of Small Vectors - Cmte.

FDA should require complete sequencing of gene transfer vectors up to 40 kilo bases in size before initiation of a Phase I gene transfer therapy clinical trial, the Biological Response Modifiers Advisory Committee recommended Nov. 16.

Genzyme Purchase Of Cell Genesys Shows Confidence In Gene Therapy Future

Genzyme's $350 mil. acquisition of Cell Genesys represents a vote of confidence in gene therapy after concerns about the death of a clinical trial subject.

Related Content

UsernamePublicRestriction

Register

PS034905

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel